Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Boston Convention and Exhibition Center

24 jun 2018 8:30 a.m. - 24 jun 2018 12:00 p.m.

415 Summer Street, , Boston, MA 02210 , USA

#27: The Evolving Role of Payers in Drug Development: Pricing, Pharmacoeconomics, and Health Technology Assessment

Instructors

Jack M. Mycka

Jack M. Mycka

Global President and CEO, Medical Marketing Economics LLC (MME), United States

As MME’s Global President & CEO, Jack provides critical global support for strategic marketing and pricing decisions to clients in the biotech and pharmaceutical industries. As a recognized expert consultant since 2001, he has successfully completed engagements encompassing many product classes and therapeutic areas and markets, including chronic care, oncology, injectable, and other specialty products all centered on value and its interaction with pricing, payers, reimbursement, and marketing in general at both MME and predecessor organizations.

Richard J. Willke, PhD

Richard J. Willke, PhD

Chief Science Officer, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), United States

Dick became ISPOR’s first Chief Science Officer in 2016, where he develops, leads, and supports strategic initiatives related to research, scientific, and content priorities. Prior to ISPOR he worked for 25 years at Pfizer and its legacy companies, where he retired as a vice president in the HEOR group. He received a PhD in economics from Johns Hopkins, taught economics at Ohio State, and was senior economist at the American Medical Association. He has been a co-editor for Value in Health, on AHRQ, NIH, and PCORI study sections, and chaired the PhRMA Health Outcomes Committee.

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.